Core Viewpoint - Meituan's Tabbit AI browser has entered public beta, aiming to redefine the browsing experience by integrating AI capabilities deeply into its functionality, targeting office workers, students, and content creators [1][2]. Group 1: Product Overview - Tabbit AI browser supports both macOS and Windows platforms and is currently available for free without an invitation code [1]. - The browser is designed to automate tasks such as opening web pages, extracting information, filling forms, and integrating data across platforms, enhancing user efficiency [1][2]. - Unlike traditional browsers that primarily serve as web browsing tools, Tabbit aims to achieve "human-machine collaboration" through features like "smart agents," "tips," and "scripts" [1]. Group 2: Market Context - The browser market is dominated by Microsoft IE/Edge and Google Chrome, but the rise of generative AI presents an opportunity for tech companies to innovate traditional browsers [1]. - Many existing AI browsers in the market add AI functionalities on top of traditional browser architectures, maintaining the core browsing logic [1][3]. Group 3: Competitive Landscape - Other players in the AI browser space include Alibaba's Quark AI browser and a Silicon Valley startup, The Browser Company, which is developing an AI-native browser that eliminates traditional tabs [3]. - Meituan's Tabbit is part of a broader trend where companies are integrating AI deeply into browser functionalities to enhance user experience [3]. Group 4: Company Strategy - Meituan's "Light Year Beyond" team, which developed Tabbit, was founded by Meituan's co-founder Wang Huiwen and has received significant investment, with a valuation exceeding $600 million [3]. - Meituan's CEO Wang Xing has expressed a strong interest in AI, outlining a three-tier AI strategy focusing on workplace efficiency, product enhancement, and building internal language models [4]. Group 5: Challenges and Opportunities - Despite the potential of AI browsers, Meituan has faced challenges in gaining market presence, especially in the C-end AI application space, where competitors have been more aggressive [6][7]. - The launch of Tabbit may not immediately change Meituan's position in the AI landscape, but it signals the company's commitment to C-end AI applications [7].

Core Viewpoint - The company, 特海国际 (09658.HK), expects significant revenue and profit growth for the fiscal year ending December 31, 2025, compared to the previous year [1] Financial Performance - The company anticipates revenue of no less than $840 million for the fiscal year ending December 31, 2025, an increase from $778 million for the fiscal year ending December 31, 2024 [1] - The expected profit attributable to the owners of the company is projected to be no less than $34 million for the fiscal year ending December 31, 2025, up from approximately $21.8 million for the fiscal year ending December 31, 2024 [1]

Core Viewpoint - The automotive industry's shift towards "intelligentization" is accelerating, with a focus on chip technology as a critical battleground for competitive advantage in autonomous driving and AI applications [1][4]. Group 1: NIO's Strategic Moves - NIO's subsidiary, Anhui Shenqi Technology Co., Ltd., completed its first round of equity financing, raising over 2.2 billion RMB, with a post-investment valuation nearing 10 billion RMB [3]. - The financing will support the continued research and development of high-end, competitive chip products, aiding NIO's long-term strategy in autonomous driving and embodied intelligence [3][5]. - NIO retains a 62.7% stake in Shenqi, while external investors hold 27.3%, and 10% is held by management incentive entities, allowing NIO to maintain control over core technologies [3][6]. Group 2: Technological Advancements - The Shenqi NX9031 chip is the world's first mass-produced 5nm automotive-grade high-performance driving chip, showcasing significant technological advancements [6]. - The NX9031 features over 50 billion transistors, a 32-core CPU architecture, and a self-developed ISP capable of processing 6.5G pixels per second, with a latency of less than 5ms [7]. - NIO's strategy of self-research and development in chip technology aims to reduce costs significantly, with each vehicle potentially saving 10,000 RMB by replacing multiple purchased chips with a single self-developed chip [7]. Group 3: Industry Trends and Competition - The automotive industry is undergoing a transformation where AI technology is becoming essential, shifting from an optional to a mandatory focus for companies aiming to be leaders in the sector [9]. - Major players like Xpeng and Li Auto are restructuring their organizations to enhance their AI capabilities, indicating a broader trend of traditional automakers evolving into AI technology companies [9][10]. - The competition for AI chips is intensifying, as companies recognize that the core competitiveness of vehicles is shifting from traditional components to AI-driven capabilities [10][11]. Group 4: Future Prospects - The successful financing of Shenqi reflects a revaluation of technology investments in the automotive sector, emphasizing the importance of high-barrier, long-cycle technology [12]. - The ability of Shenqi to maintain stable supply to NIO while expanding into new markets, such as embodied robotics, will be crucial for its future success [12]. - The automotive AI competition is set to escalate in 2026, with NIO positioning itself at the forefront of this evolution through its advancements in chip technology [12].

Core Viewpoint - China National Pharmaceutical Group has received approval from the National Medical Products Administration (NMPA) for its self-developed innovative drug, Rovaxitinib tablets (brand name: Anxu), for the first-line treatment of adult patients with intermediate-2 or high-risk primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF), or post-essential thrombocythemia myelofibrosis (PET-MF) [1] Group 1 - Rovaxitinib demonstrated excellent efficacy and safety in a Phase II clinical study compared to hydroxyurea in treating intermediate-2 and high-risk myelofibrosis patients [1] - The study results indicated that 58.33% of patients in the Rovaxitinib group achieved a spleen volume reduction of ≥35% (SVR35) at week 24, with 63.89% achieving SVR35 at any time point [1] - The average duration of SVR35 was 8.31 months, and the total symptom score improvement of ≥50% (TSS50) rate reached 77.78% [1] Group 2 - The overall tolerability of the drug was good, with an incidence rate of adverse reactions of grade ≥3 at approximately 40%, and anemia occurrence also around 40% [1] - The treatment discontinuation rate was only 6.7% [1]

雅居乐集团(03383)发布公告，于2026年3月2日的高等法院聆讯中，高等法院颁令将呈请聆讯延期至 2026年6月29日。 ...

智通财经APP讯，雅居乐集团(03383)发布公告，于2026年3月2日的高等法院聆讯中，高等法院颁令将呈 请聆讯延期至2026年6月29日。 ...

格隆汇3月2日丨雅居乐集团(03383.HK)公告，内容有关呈请人对公司提出呈请。于2026年3月2日的高等 法院聆讯中，高等法院颁令将呈请聆讯延期至2026年6月29日。 ...

敏华控股(01999)发布公告，于2026年3月2日，本公司根据于2024年6月24日采纳的本公司股份奖励计划 的规则，向24位本集团雇员授出奖励，当中涉及本公司将予发行的股份总数289.8万股，相当于授出日 期38.78亿股已发行股份的约0.07%，惟须待承授人接纳后方可作实。 ...

格隆汇3月2日丨敏华控股(01999.HK)宣布，于2026年3月2日，公司根据于2024年6月24日采纳的公司股 份奖励计划的规则，向24位集团雇员授出奖励，当中涉及公司将予发行的股份总数289.8万股，相当于 授出日期已发行股份的约0.07%，惟须待承授人接纳后方可作实。 ...

智通财经APP讯，敏华控股(01999)发布公告，于2026年3月2日，本公司根据于2024年6月24日采纳的本 公司股份奖励计划的规则，向24位本集团雇员授出奖励，当中涉及本公司将予发行的股份总数289.8万 股，相当于授出日期38.78亿股已发行股份的约0.07%，惟须待承授人接纳后方可作实。 ...